-
Mashup Score: 134Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial - 2 month(s) ago
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. POUT was a phase III, randomized, open-label trial, including 261 patients with muscle-invasive or lymph node–positive, nonmetastatic upper tract urothelial cancer (UTUC) randomly assigned after radical nephroureterectomy to platinum-based chemotherapy (132) or surveillance (129). Primary outcome analysis demonstrated that chemotherapy improved disease-free survival (DFS). At that time, the planned secondary outcome analysis of overall survival (OS) was immature. By February 2022, 50 and 67 DFS events had occurred in the chemotherapy and surveillance groups, respectively
Source: ascopubs.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 6
People who watch at least five hours of TV a day are found to be more likely to need to wake up and urinate at least twice a night
Source: www.theguardian.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 112Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial - 3 month(s) ago
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. POUT was a phase III, randomized, open-label trial, including 261 patients with muscle-invasive or lymph node–positive, nonmetastatic upper tract urothelial cancer (UTUC) randomly assigned after radical nephroureterectomy to platinum-based chemotherapy (132) or surveillance (129). Primary outcome analysis demonstrated that chemotherapy improved disease-free survival (DFS). At that time, the planned secondary outcome analysis of overall survival (OS) was immature. By February 2022, 50 and 67 DFS events had occurred in the chemotherapy and surveillance groups, respectively
Source: ascopubs.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 109Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial - 3 month(s) ago
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. POUT was a phase III, randomized, open-label trial, including 261 patients with muscle-invasive or lymph node–positive, nonmetastatic upper tract urothelial cancer (UTUC) randomly assigned after radical nephroureterectomy to platinum-based chemotherapy (132) or surveillance (129). Primary outcome analysis demonstrated that chemotherapy improved disease-free survival (DFS). At that time, the planned secondary outcome analysis of overall survival (OS) was immature. By February 2022, 50 and 67 DFS events had occurred in the chemotherapy and surveillance groups, respectively
Source: ascopubs.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 24
The Journal of Pathology: Clinical Research, official OA Journal for the Pathological Society, publishes both basic biomedical science and clinical medicine research.
Categories: General Medicine News, UrologyTweet
-
Mashup Score: 2
Bacillus Calmette-Guérin (BCG) is the standard of care for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). BCG in combination with programmed cell death-1 (PD-1) inhibitors may yield greater anti-tumor activity compared with either agent alone. CREST is a phase III study evaluating the efficacy and safety of the subcutaneous PD-1 inhibitor sasanlimab in combination with BCG for patients with BCG-naive high-risk NMIBC. Eligible participants are randomized to receive sasanlimab plus BCG (induction ± maintenance) or BCG alone for up to 25 cycles within 12 weeks of TURBT. The primary outcome is event-free survival. Secondary outcomes include additional efficacy end points and safety. The target sample size is around 1000 participants.
Source: www.futuremedicine.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 8
The long-awaited inaugural episode of the European Urology Oncology (EUO) podcast is here! Host, Dr Renu Eapen (Melbourne) highlights two key papers from the December issue of the journal (details below). Tune in for interviews with key authors and local experts. The regular EUO BIO segment highlights other key papers, upcoming meetings, and current affairs in GU oncology. This episode’s EUO BIO features new Editor-in-Chief, Professor Morgan Roupret.Available as a classic audio podcast in all the usual places: (insert buzzsprout link)Priority papers:1. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer https://euoncology.europeanurology.com/article/S2588-9311(23)00203-1/fulltextFeatured authors – Professor Peter Albers & Dr Agne Krilaviciute (Heidelberg, Germany) 2. Oncological Outcomes for Patients with European Association of Urology Very High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy
Source: www.buzzsprout.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 8
The long-awaited inaugural episode of the European Urology Oncology (EUO) podcast is here! Host, Dr Renu Eapen (Melbourne) highlights two key papers from the December issue of the journal (details below). Tune in for interviews with key authors and local experts. The regular EUO BIO segment highlights other key papers, upcoming meetings, and current affairs in GU oncology. This episode’s EUO BIO features new Editor-in-Chief, Professor Morgan Roupret.Available as a classic audio podcast in all the usual places: (insert buzzsprout link)Priority papers:1. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer https://euoncology.europeanurology.com/article/S2588-9311(23)00203-1/fulltextFeatured authors – Professor Peter Albers & Dr Agne Krilaviciute (Heidelberg, Germany) 2. Oncological Outcomes for Patients with European Association of Urology Very High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy
Source: www.buzzsprout.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 12The University of Sheffield hiring Professorships in Cancer Research in Sheffield, England, United Kingdom | LinkedIn - 5 month(s) ago
Posted 9:21:53 PM. The University of Sheffield is recruiting high-performing cancer research leaders to join us to…See this and similar jobs on LinkedIn.
Source: www.linkedin.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 23Cancer Research leadership roles - Sheffield, South Yorkshire - 5 month(s) ago
We are looking to appoint 5 or more academics and clinical academics into a range of roles including professorial
Source: www.bmj.comCategories: General Medicine News, UrologyTweet
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial | Journal of Clinical Oncology https://t.co/W2JNqSYV7d